These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 4641756)

  • 1. Preliminary clinical experience with cis-diamminedichloroplatinum (II) (NSC 119875, CACP).
    Rossof AH; Slayton RE; Perlia CP
    Cancer; 1972 Dec; 30(6):1451-6. PubMed ID: 4641756
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical trials of cis-diamminedichloroplatinum (NSC-119875).
    Lippman AJ; Helson C; Helson L; Krakoff IH
    Cancer Chemother Rep; 1973 Apr; 57(2):191-200. PubMed ID: 4126381
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical evaluation of toxic effects of cis-diamminedichloroplatinum (NSC-119875)--phase I clinical study.
    Talley RW; O'Bryan RM; Gutterman JU; Brownlee RW; McCredie KB
    Cancer Chemother Rep; 1973; 57(4):465-71. PubMed ID: 4762440
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of cis-diamminedichloroplatinum (NSC-119875) on hearing function in man.
    Piel IJ; Meyer D; Perlia CP; Wolfe VI
    Cancer Chemother Rep; 1974; 58(6):871-5. PubMed ID: 4447919
    [No Abstract]   [Full Text] [Related]  

  • 5. 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in patients with gastrointestinal carcinoma.
    Moertel CG; Reitemeier RJ; Hahn RG; Schutt AJ
    Cancer Chemother Rep; 1970 Dec; 54(6):471-3. PubMed ID: 4946016
    [No Abstract]   [Full Text] [Related]  

  • 6. Preclinical toxicology of alpha-2'-deoxythioguanosine (NSC-71851).
    Henry MC; DiDomenico E
    Cancer Chemother Rep 3; 1974 Sep; 5(1):9-14. PubMed ID: 4213304
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical and pharmacological studies with cis-diamminedichloroplatinum (II).
    DeConti RC; Toftness BR; Lange RC; Creasey WA
    Cancer Res; 1973 Jun; 33(6):1310-5. PubMed ID: 4515709
    [No Abstract]   [Full Text] [Related]  

  • 8. Initial clinical trials with 1,1-diphenyl-2-propynyl cyclohexanecarbamate (NCS-112682).
    Luce JK; Bodey GP
    Cancer Chemother Rep; 1970 Apr; 54(2):131-4. PubMed ID: 4946003
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of malignant melanoma with camptothecin (NSC-100880).
    Gottlieb JA; Luce JK
    Cancer Chemother Rep; 1972 Feb; 56(1):103-5. PubMed ID: 5030802
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of the combination of hexamethylmelamine (NSC-13875) and methotrexate (NSC-740) in carcinoma of the lung.
    Weiss AJ; Wilson WL
    Cancer Chemother Rep; 1971 Jun; 55(3):299-302. PubMed ID: 5115850
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical studies of Platinum Coordination compounds in the treatment of various malignant diseases.
    Hill JM; Loeb E; MacLellan A; Hill NO; Khan A; King JJ
    Cancer Chemother Rep; 1975; 59(3):647-59. PubMed ID: 1203889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute toxicologic and pathologic effects of cis-diamminedichloroplatinum (NSC-119875) in the male rat.
    Kociba RJ; Sleight SD
    Cancer Chemother Rep; 1971 Feb; 55(1):1-8. PubMed ID: 5121647
    [No Abstract]   [Full Text] [Related]  

  • 13. Some preliminary observations during the phase I clinical testing of cis-dichlorodiammineplatinum. II.
    Fiserová J; Dostálová O; Drobník J; Dohnalová J; Holík F
    Neoplasma; 1973; 20(2):221-2. PubMed ID: 4707844
    [No Abstract]   [Full Text] [Related]  

  • 14. Hexamethylmelamine (NSC-13875) for acute leukemia and solid tumors in children.
    Dyment PG; Fernbach DJ; Sutow WW
    J Clin Pharmacol New Drugs; 1973; 13(2):111-3. PubMed ID: 4568295
    [No Abstract]   [Full Text] [Related]  

  • 15. Toxic effects of cis-dichlorodiammineplatinum(II) in man.
    Von Hoff DD; Schilsky R; Reichert CM; Reddick RL; Rozencweig M; Young RC; Muggia FM
    Cancer Treat Rep; 1979; 63(9-10):1527-31. PubMed ID: 387223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate.
    Bodenner DL; Dedon PC; Keng PC; Katz JC; Borch RF
    Cancer Res; 1986 Jun; 46(6):2751-5. PubMed ID: 3009000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The enhanced therapeutic effect of cis-platinum (II) diamminodichloride against L1210 leukemia when combined with cyclophosphamide or 1,2-bis(3,5-dioxopiperazine-1-yl)propane or several other antitumor agents.
    Woodman RJ; Sirica AE; Gang M; Kline I; Venditti JM
    Chemotherapy; 1973; 18(3):169-83. PubMed ID: 4119363
    [No Abstract]   [Full Text] [Related]  

  • 18. Qualitative and quantitative toxicity of sublethal doses of methyl-CCNU in BDF1 mice.
    Denine EP; Harrison SD; Peckham JC
    Cancer Treat Rep; 1977; 61(3):409-17. PubMed ID: 872140
    [No Abstract]   [Full Text] [Related]  

  • 19. 6-Mercaptopurine (NSC-755) given intermittently in high doses: phase II study.
    Fink DJ; Foye LV
    Cancer Chemother Rep; 1970 Feb; 54(1):31-4. PubMed ID: 4945996
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase II study of CCNU (NSC-79037) in the treatment of advanced gastrointestinal cancer.
    Klaassen DJ; Rapp E
    Cancer Chemother Rep; 1974; 58(5 Pt 1):667-9. PubMed ID: 4426046
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.